Literature DB >> 7747467

Separation of sequence requirements for HSV-1 Vmw110 multimerisation and interaction with a 135-kDa cellular protein.

M Meredith1, A Orr, M Elliott, R Everett.   

Abstract

Herpes simplex virus type 1 immediate-early polypeptide Vmw110 (ICP0) is a general transactivator of gene expression in transfection assays and is required for the fully efficient onset of viral lytic replication. It has also been implicated in the process of viral reactivation from latency. Its mechanism of action is unknown, but any involvement in latency requires interactions between viral and host factors. We have previously shown that Vmw110 binds to a 135-kDa cellular protein. In this paper we define a short region towards the C-terminal end of Vmw110 that is required for the 135-kDa protein interaction in virus-infected cells and in vitro. We also confirm that the C-terminal region of Vmw110 contains residues that are responsible for the multimerisation of the protein; these sequences are at least partially distinct from those involved in 135-kDa binding. Both multimerisation and 135-kDa protein interaction are required for full viral infectivity, and elimination of these functions affects the normal interactions between Vmw110 and cellular nuclear structures that contain the PML protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747467     DOI: 10.1006/viro.1995.1241

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  60 in total

1.  Requirements for the nuclear-cytoplasmic translocation of infected-cell protein 0 of herpes simplex virus 1.

Authors:  P Lopez; C Van Sant; B Roizman
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.

Authors:  R D Everett; W C Earnshaw; J Findlay; P Lomonte
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

3.  Conserved region CR2 of Epstein-Barr virus nuclear antigen leader protein is a multifunctional domain that mediates self-association as well as nuclear localization and nuclear matrix association.

Authors:  Michiko Tanaka; Akihiko Yokoyama; Mie Igarashi; Go Matsuda; Kentaro Kato; Mikiko Kanamori; Kanji Hirai; Yasushi Kawaguchi; Yuji Yamanashi
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  ICP0 induces the accumulation of colocalizing conjugated ubiquitin.

Authors:  R D Everett
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins.

Authors:  J Parkinson; R D Everett
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes.

Authors:  Rongtuan Lin; Ryan S Noyce; Susan E Collins; Roger D Everett; Karen L Mossman
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 7.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Recruitment of herpes simplex virus type 1 immediate-early protein ICP0 to the virus particle.

Authors:  Kevin Maringer; Gillian Elliott
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

9.  The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.

Authors:  C Van Sant; R Hagglund; P Lopez; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

10.  Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner.

Authors:  Chris Boutell; Roger D Everett
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.